IBD patients discontinuing medication due to side effects concerns worldwide 2019

As of 2019, around 46 percent of patients with ulcerative colitis worldwide reported discontinuing corticosteriod due to concerns about side effects, compared to around 41 percent of patients with Crohn's disease. This statistic illustrates the percentage of IBD patients worldwide reporting discontinuing medication due to concerns about side effects as of 2019.

Percentage of IBD patients worldwide reporting discontinuing medication due to concerns about side effects as of 2019*

Characteristic	Patients with Crohn's disease	Patients with ulcerative colitis
Corticosteroid	41%	46%
Immunomodulator	33%	33%
TNF inhibitor	33%	27%
5-ASA	28%	28%
Anti-integrin	11%	11%

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

January 2021

More information

Region

Worldwide, North America, Europe

Survey time period

August 16 to November 10, 2019

Number of respondents

842 respondents

Age group

18 years and older

Method of interview

Face-to-face interview

Supplementary notes

* IBD: Inflammatory Bowel Disease
The survey count represents 523 patients with Crohn's disease, and 319 patients with ulcerative colitis. Respondents were from the United States (39%), Spain (12%), France (10%), Germany (10%), the United Kingdom (10%), Italy (9%), and Canada (9%).

Citation formats